The $MDCO management emphasized flexibility in the drug price and potential buyout of the company. I can think of three biotechs which might be interested in buying the company. Regeneron may want to buy it because of their patent issues with Praluent, and Amgen might be interested in too if inclisiran is in the class of its own as the management suggested. Biogen badly needs cash generators for the long term. $ALNY may rise modestly after the Sept. 2 late-breaking data release.